Archives
Isoprinosine (Inosine Pranobex): Immunomodulatory Agent f...
Isoprinosine (Inosine Pranobex): Immunomodulatory Agent for Viral Infection Control
Executive Summary: Isoprinosine (inosine pranobex) is a crystalline immunomodulatory compound composed of acetaminobenzoic acid, dimethylaminoisopropanol, and inosine in a 3:3:1 ratio. It is effective in both in vitro and in vivo models for inhibiting herpesvirus replication and boosting antiviral immunity (50–400 μg/mL, 37°C, 14-day mouse model) (Dai et al., 2024). Clinical studies confirm safety and efficacy in acute respiratory viral infections in adults under 50 years old. The compound exhibits high water and DMSO solubility, is stable at -20°C, and offers a lower risk of resistance than conventional antivirals. Unique mechanistic properties differentiate Isoprinosine from standard treatments, expanding options for viral infection immunomodulation (product page).
Biological Rationale
Viral infections such as those caused by herpesviruses and respiratory viruses pose substantial global health burdens. Herpesviruses, including HHV-1, utilize complex nuclear egress mechanisms involving host and viral proteins (Dai et al., 2024). Conventional antivirals often target viral enzymes, leading to potential resistance. Immunomodulatory agents like Isoprinosine leverage the host immune system to combat viral replication, offering an alternative strategy with typically reduced toxicity and resistance development (More at Mouse IFN-γ). Isoprinosine’s dual action—immune enhancement and direct antiviral effect—positions it as a versatile tool in immunotherapy and infection management.
Mechanism of Action of Isoprinosine
Isoprinosine’s mechanism centers on modulating immune system activity and directly inhibiting viral replication. The compound increases leukocyte and neutrophil counts, augments virus-neutralizing antibody titers, and suppresses atypical lymphocyte formation in infected models. In vitro, Isoprinosine inhibits HHV-1 (herpes simplex virus) replication in a dose-dependent fashion (50–400 μg/mL, 37°C), and this activity is potentiated when combined with interferon-alpha (1000 IU/mL) (Dai et al., 2024). In vivo, Balb/c mice treated with Isoprinosine after murine gammaherpesvirus 68 infection showed significant reductions in viral titers after 14 days. The effects attenuate after 120–150 days, indicating a time-dependent window of efficacy.
Evidence & Benchmarks
- Isoprinosine inhibits HHV-1 replication in vitro at 50–400 μg/mL, 37°C (Dai et al., 2024, DOI).
- Combination of Isoprinosine (400 μg/mL) and interferon-alpha (1000 IU/mL) enhances antiviral activity in cell culture (Dai et al., 2024, DOI).
- In vivo, Isoprinosine increases leukocyte counts, neutrophil percentages, and antiviral antibodies in Balb/c mice infected with murine gammaherpesvirus 68 (14 days, 37°C, Dai et al., 2024, DOI).
- Clinical trials demonstrate safety and efficacy in treating acute respiratory viral infections in healthy, non-obese adults under 50 years old (clinical documentation, product page).
- Isoprinosine is highly soluble in water (≥58.7 mg/mL) and DMSO (≥96 mg/mL); insoluble in ethanol (specification sheet, product page).
This article extends the mechanistic and translational detail provided in AImmunity.net by focusing on recent in vitro and in vivo benchmarks and direct comparisons with interferon-based therapy.
Applications, Limits & Misconceptions
Isoprinosine finds utility as an immunomodulatory agent for viral infections, especially where conventional antivirals are less effective or resistance is likely. It is indicated for acute respiratory viral infections and herpesvirus-related conditions in preclinical and clinical settings. The molecular weight (1115.2) and CAS number (36703-88-5) enable precise compound tracking. Its solubility profile supports formulation in various aqueous and DMSO-based buffers, but not ethanol.
Compared to existing reviews such as CY5-Amine.com, this article integrates the latest evidence on dose-dependent effects and time-limited efficacy in animal models, clarifying the compound’s real-world translational boundaries.
Common Pitfalls or Misconceptions
- Isoprinosine is not a cure for chronic or latent herpesvirus infections; its effects diminish after 120–150 days in vivo.
- Ineffective against non-viral pathogens (e.g., bacteria, fungi).
- Not proven effective in obese or elderly populations beyond 50 years of age.
- Long-term storage of prepared solutions is not recommended; prepare fresh for each use.
- Insoluble in ethanol—using ethanol as a vehicle will result in precipitation and loss of activity.
Workflow Integration & Parameters
For in vitro studies, Isoprinosine is typically applied at 50–400 μg/mL in water or DMSO-based media at 37°C. For in vivo mouse models, dosing regimens align with the 14-day window for maximal immune enhancement and viral titer reduction. Store the crystalline solid at -20°C; reconstituted solutions should be used immediately and not stored long-term. The C4417 kit provides quality-controlled material for research use.
This article updates prior guidance from IFN-y.com by detailing optimal storage, solvent compatibility, and specific dosing benchmarks for translational workflows.
Conclusion & Outlook
Isoprinosine is a validated immunomodulatory agent with both direct and indirect antiviral actions, effective in acute viral infections and supported by robust in vitro, in vivo, and clinical data. Its unique mechanism and safety profile make it a valuable tool for preclinical and translational research in viral immunotherapy. Future directions include expanding its clinical indications, optimizing combination regimens (e.g., with interferons), and clarifying its long-term immunomodulatory effects. For detailed protocols and product sourcing, see the official Isoprinosine product page.